Biomea Fusion vs Viking Therapeutics
BMEA and VKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMEA and VKTX compare
Viking Therapeutics is the larger company, worth 82 times as much as Biomea Fusion ($3.6B against $44.3M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMEA | VKTX |
|---|---|---|
| Size and price | ||
| Market cap | $44.3M | $3.6B |
| Share price | $0.611 | $28.44 |
| Change, 1 year | −55.4% | −24.7% |
| Change, 5 years | −94.3% | 404% |
| Beta (5Y) | 0.82 | 1.57 |
| Employees | 41 | 53 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 5.8× (better) | 6.2× |
| Profitability | ||
| Return on equity | −192% | −96.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.17 | 7.27 (better) |
| Altman Z-score | −27.68 | 2.55 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 34.8% | 59.4% |
| Held by insiders | 5.5% | 2.7% |
| Insider net buying, 12 months | $152K (better) | −$18.2M |
| Short interest, % of float | 22.2% | 19.5% |
Go deeper
- BMEA stock overview
- BMEA income statement
- BMEA valuation and score
- VKTX stock overview
- VKTX income statement
- VKTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.